Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial

被引：6

作者：

van Nes, J. G. H. ^{[1
]}

Seynaeve, C. ^{[2
]}

Maartense, E. ^{[3
]}

Roumen, R. M. H. ^{[4
]}

de Jong, R. S. ^{[5
]}

Beex, L. V. A. M. ^{[6
]}

Kranenbarg, W. M. Meershoek-Klein ^{[7
]}

Putter, H. ^{[8
]}

Nortier, J. W. R. ^{[9
]}

van de Velde, C. J. H. ^{[1
]}

机构：

[1] Leiden Univ, Med Ctr, Dept Surg, NL-2300 RC Leiden, Netherlands

[2] Daniel Denhoed Canc Ctr, Erasmus Med Ctr, Dept Med Oncol, Rotterdam, Netherlands

[3] Reinier Graaf Gasthuis, Dept Internal Med, Delft, Netherlands

[4] Maxima Med Ctr, Dept Surg, Veldhoven, Netherlands

[5] Martini Hosp, Dept Internal Med, Groningen, Netherlands

[6] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, NL-6525 ED Nijmegen, Netherlands

[7] Leiden Univ, Med Ctr, Datactr Surg, NL-2300 RC Leiden, Netherlands

[8] Leiden Univ, Med Ctr, Dept Med Stat, NL-2300 RC Leiden, Netherlands

[9] Leiden Univ, Med Ctr, Dept Med Oncol, NL-2300 RC Leiden, Netherlands

来源：

ANNALS OF ONCOLOGY | 2010年 / 21卷 / 05期

关键词：

breast cancer; endocrine therapy; guideline; patterns of care; AROMATASE INHIBITORS; THERAPY; WOMEN; SURVIVAL; RECOMMENDATIONS; NETHERLANDS; MASTECTOMY; MANAGEMENT; LETROZOLE; SURGERY;

D O I：

10.1093/annonc/mdp419

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Methods: Clinicopathological characteristics, carried out local treatment strategies and adjuvant chemotherapy data were collected. Results: From 2001 to January 2006, 2754 Dutch patients were randomised to the study. Mean age of patients was 65 years (standard deviation 9). Tumours were < 2 cm in 46% (within CCCRs 39%-50%), node-negative disease varied from 25% to 45%, and PgR status was determined in 75%-100% of patients. Mastectomy was carried out in 55% (45%-70%), sentinel lymph node procedure in 68% (42%-79%) and axillary lymph node dissections in 77% (67%-83%) of patients, all different between CCCRs (P < 0.0001). Adjuvant chemotherapy was given in 15%-70% of eligible patients (P < 0.001). Discussion: In spite of national guidelines, breast cancer treatment on specific issues widely varied between the various Dutch regions. These data provide valuable information for breast cancer organisations indicating (lack of) guideline adherence and areas for breast cancer care improvement.

引用

页码：974 / 982

页数：9

共 50 条

[31] Pharmacokinetic and pharmacodynamic interaction of adjuvant tamoxifen and exemestane in postmenopausal women treated for early stage breast cancer.
Hutson, PR
Love, RR
Cleary, JF
Kim, K
BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S74 - S74
[32] Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: Report of a tamoxifen exemestane adjuvant Multicenter trial substudy
Jones, Stephen E.
Cantrell, James
Vukelja, Svetislava
Pippen, John
O'Shaughnessy, Joyce
Blum, Joanne L.
Brooks, Robert
Hartung, Nicole L.
Negron, Angel G.
Richards, Donald A.
Rivera, Ragene
Holmes, Frankie Ann
Chittoor, Sreeni
Whittaker, Thomas L.
Bordelon, James H.
Ketchel, Steven J.
Davis, Jennifer C.
Ilegbodu, Des
Kochis, Jean
Asmar, Lina
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (30) : 4765 - 4771
[33] Optimal use of aromatase inhibitors for adjuvant treatment of hormone-sensitive early breast cancer: Up front or sequenced after tamoxifen?
Cuzick, J.
Sasieni, P.
Howell, A.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[34] Five years of exemestane as initial therapy compared to tamoxifen followed by exemestane for a total of 5 years: the TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone receptor-positive early breast cancer
Hasenburg, A.
van de Velde, C. J. H.
Seynaeve, C.
Rea, D. W.
Vannetzel, J.
Paridaens, R.
Markopoulos, C.
Hozumi, Y.
Putter, H.
Jones, S. E.
EJC SUPPLEMENTS, 2010, 8 (03): : 62 - 62
[35] Physical Activity and Survival of Postmenopausal, Hormone Receptor-Positive Breast Cancer Patients Results of the Tamoxifen Exemestane Adjuvant Multicenter Lifestyle Study
de Glas, Nienke A.
Fontein, Duveken B. Y.
Bastiaannet, Esther
Pijpe, Anouk
De Craen, Anton J. M.
Liefers, Gerrit-Jan
Nortier, Hans J. W. R.
de Haes, Hanneke J. C. J. M.
de Velde, Cornelis J. H. van
van Leeuwen, Flora E.
CANCER, 2014, 120 (18) : 2847 - 2854
[36] The effects on lipids of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer
Gonnelli, S.
Montagnani, A.
Cadirni, A.
Caffarelli, C.
Montomoli, M.
Campagna, M. S.
Petrioli, R.
Del Santo, K.
Cuda, C.
Nuti, R.
ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 409 - 409
[37] Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial
Derks, Marloes G. M.
Blok, Erik J.
Seynaeve, Caroline
Nortier, Johan W. R.
Kranenbarg, Elma Meershoek-Klein
Liefers, Gerrit-Jan
Putter, Hein
Kroep, Judith R.
Rea, Daniel
Hasenburg, Annette
Markopoulos, Christos
Paridaens, Robert
Smeets, Jan B. E.
Dirix, Luc Y.
van de Velde, Cornelis J. H.
LANCET ONCOLOGY, 2017, 18 (09): : 1211 - 1220
[38] Switching to adjuvant exemestane after tamoxifen improves disease-free survival in postmenopausal women with hormone receptor-positive early breast cancer
不详
Drugs & Therapy Perspectives, 2007, 23 (5) : 1 - 4
[39] Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial
BREAST, 2005, 14 : S38 - S38
[40] Endocrine effects of adjuvant letrozole versus tamoxifen in hormone responsive postmenopausal early breast cancer patients: results from the HOBOE randomized trial
Morabito, A.
Rossi, E.
Di, Rella F.
Esposito, G.
Gravina, A.
Labonia, V
Landi, G.
Nuzzo, F.
Pacilio, C.
De Maio, E.
Piccirillo, M. C.
De Feo, G.
D' Aiulo, G.
Botti, G.
Gallo, C.
Perrone, F.
de Matteis, A.
CANCER RESEARCH, 2009, 69 (02) : 151S - 151S

← 1 2 3 4 5 →